(Incorporated in Delaware)

We are a clinical-stage biotech company focused on developing subcutaneous treatments for rare blood coagulation disorders. Our lead therapeutic candidate, sutacimig – also known as HMB-001, has completed Phase 2 trials and it’s ready for Phase 3 for the treatment of Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency. Our therapeutic candidate, HMB-002, is in Phase 1/2 trials for Von Willebrand Disease. 

Note: Net loss is for the year that ended Dec. 31, 2025.

Note: The company has not generated any revenue.

(Note: Hemab Therapeutics Holdings,  Inc. upsized its IPO at pricing – to 16.75 million shares – up from 15.0 million shares – its upsizing earlier in the day – and priced the IPO at $18.00 – to raise $301.5 million on Thursday night, April 30, 2026. Background: Hemab Therapeutics upsized its IPO to 15.0 million shares – up from 11.76 million originally – and kept the price range at $16.00 to $18.00 – to raise $255.0 million, if priced at the $17.00 mid-point of its range, according to its S-1/A filing early Thursday, April 30, 2026. Background: Hemab Therapeutics disclosed the terms for its IPO on April 27, 2026, in an S-1/A filing: 11.76 million shares at a price range of $16.00 to $18.00 – to raise $199.92 million, if priced at the $17.00 mid-point of its range. Background: Hemab Therapeutics Holdings, Inc. filed its S-1 on April 10, 2026, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)